Cargando…

Vitamin D Deficiency and Outcome of COVID-19 Patients

Infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses an enormous challenge to health care systems throughout the world. Without causal treatment, identification of modifiable prognostic factors may help to improve outcomes. To explore possible associations of vitamin...

Descripción completa

Detalles Bibliográficos
Autores principales: Radujkovic, Aleksandar, Hippchen, Theresa, Tiwari-Heckler, Shilpa, Dreher, Saida, Boxberger, Monica, Merle, Uta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551780/
https://www.ncbi.nlm.nih.gov/pubmed/32927735
http://dx.doi.org/10.3390/nu12092757
_version_ 1783593254042730496
author Radujkovic, Aleksandar
Hippchen, Theresa
Tiwari-Heckler, Shilpa
Dreher, Saida
Boxberger, Monica
Merle, Uta
author_facet Radujkovic, Aleksandar
Hippchen, Theresa
Tiwari-Heckler, Shilpa
Dreher, Saida
Boxberger, Monica
Merle, Uta
author_sort Radujkovic, Aleksandar
collection PubMed
description Infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses an enormous challenge to health care systems throughout the world. Without causal treatment, identification of modifiable prognostic factors may help to improve outcomes. To explore possible associations of vitamin D (VitD) status with disease severity and survival, we studied 185 patients diagnosed with coronavirus disease 2019 (COVID-19) and treated at our center. VitD status at first presentation was assessed retrospectively using accredited laboratory methods. VitD deficiency was defined as serum total 25-hydroxyvitamin D level < 12 ng/mL (<30 nM). Primary endpoint was severe course of disease (i.e., need for invasive mechanical ventilation and/or death, IMV/D). Within a median observation period of 66 days (range 2–92), 23 patients required IMV. A total of 28 patients had IMV/D, including 16 deaths. Ninety-three (50%) patients required hospitalization (inpatient subgroup). A total of 41 (22%) patients were VitD deficient. When adjusted for age, gender, and comorbidities, VitD deficiency was associated with higher risk of IMV/D and death (HR 6.12, 95% CI 2.79–13.42, p < 0.001 and HR 14.73, 95% CI 4.16–52.19, p < 0.001, respectively). Similar correlations were observed in the inpatient subgroup. Our study demonstrates an association between VitD deficiency and severity/mortality of COVID-19, highlighting the need for interventional studies on VitD supplementation in SARS-CoV-2 infected individuals.
format Online
Article
Text
id pubmed-7551780
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75517802020-10-14 Vitamin D Deficiency and Outcome of COVID-19 Patients Radujkovic, Aleksandar Hippchen, Theresa Tiwari-Heckler, Shilpa Dreher, Saida Boxberger, Monica Merle, Uta Nutrients Article Infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses an enormous challenge to health care systems throughout the world. Without causal treatment, identification of modifiable prognostic factors may help to improve outcomes. To explore possible associations of vitamin D (VitD) status with disease severity and survival, we studied 185 patients diagnosed with coronavirus disease 2019 (COVID-19) and treated at our center. VitD status at first presentation was assessed retrospectively using accredited laboratory methods. VitD deficiency was defined as serum total 25-hydroxyvitamin D level < 12 ng/mL (<30 nM). Primary endpoint was severe course of disease (i.e., need for invasive mechanical ventilation and/or death, IMV/D). Within a median observation period of 66 days (range 2–92), 23 patients required IMV. A total of 28 patients had IMV/D, including 16 deaths. Ninety-three (50%) patients required hospitalization (inpatient subgroup). A total of 41 (22%) patients were VitD deficient. When adjusted for age, gender, and comorbidities, VitD deficiency was associated with higher risk of IMV/D and death (HR 6.12, 95% CI 2.79–13.42, p < 0.001 and HR 14.73, 95% CI 4.16–52.19, p < 0.001, respectively). Similar correlations were observed in the inpatient subgroup. Our study demonstrates an association between VitD deficiency and severity/mortality of COVID-19, highlighting the need for interventional studies on VitD supplementation in SARS-CoV-2 infected individuals. MDPI 2020-09-10 /pmc/articles/PMC7551780/ /pubmed/32927735 http://dx.doi.org/10.3390/nu12092757 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Radujkovic, Aleksandar
Hippchen, Theresa
Tiwari-Heckler, Shilpa
Dreher, Saida
Boxberger, Monica
Merle, Uta
Vitamin D Deficiency and Outcome of COVID-19 Patients
title Vitamin D Deficiency and Outcome of COVID-19 Patients
title_full Vitamin D Deficiency and Outcome of COVID-19 Patients
title_fullStr Vitamin D Deficiency and Outcome of COVID-19 Patients
title_full_unstemmed Vitamin D Deficiency and Outcome of COVID-19 Patients
title_short Vitamin D Deficiency and Outcome of COVID-19 Patients
title_sort vitamin d deficiency and outcome of covid-19 patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551780/
https://www.ncbi.nlm.nih.gov/pubmed/32927735
http://dx.doi.org/10.3390/nu12092757
work_keys_str_mv AT radujkovicaleksandar vitaminddeficiencyandoutcomeofcovid19patients
AT hippchentheresa vitaminddeficiencyandoutcomeofcovid19patients
AT tiwarihecklershilpa vitaminddeficiencyandoutcomeofcovid19patients
AT drehersaida vitaminddeficiencyandoutcomeofcovid19patients
AT boxbergermonica vitaminddeficiencyandoutcomeofcovid19patients
AT merleuta vitaminddeficiencyandoutcomeofcovid19patients